The request will extend a waiting period until 30 days after Optum and DaVita answer the second request, unless the parties chose to do so voluntarily. DaVita and Optum said they “have been working, and will continue to work, diligently and cooperatively with the FTC in connection with the FTC’s review.”
Optum extended its $4.9 billion offer to DaVita in December 2017. If approved and completed, the deal will add nearly 300 medical clinics to Optum’s network.
DaVita still expects the deal to close in 2018.
More articles on transactions and valuations:
California AG approves Adventist, Rideout Health affiliation
U of Mississippi Medical Center, Memorial Hospital to collaborate
Cabell Huntington CEO: Pending merger will be key, help hospital ‘flourish’ in the industry
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
